We use cookies to help provide you with the best possible online experience. Please read our Privacy Policy for information about which cookies we use and what information we collect on our site. By continuing to use this site, you agree that we may store and access cookies on your device.
One More Step to Finalize Your Registration
An activation link has been sent to your email address.
Please check the email and activate your account now. It might take few minutes to get the email.
If you did not find it, please check your spam box.
Having problem receiving the email? Send again
Still cannot receive? Contact us
Email ：PharmaSources@imsinoexpo.com
Whatsapp ：+86-13621645194
Main Sales Markets: Central/South America,Western Europe,Eastern Europe,Asia,Middle East,Africa
Monthly Production Capacity: large capacity
Contract Manufacturing: Workable
Packaging Information: According to customs' requirements
Delivery Lead Time: USP, BP, EP etc
Sample Provided: no
Payment Terms: depends, normally about 2 months
Product : Cefradine for Injection
Specification : 0.5g; 1.0g;
Standard : BP, USP
Indications:
Cefradine is used in the following instances:
Respiratory tract infections (such as tonsillitis, pharyngitis, and lobar pneumonia) caused by group A beta-hemolytic streptococci and S. pneumoniae (formerly D. pneumonia).[note 1]
Otitis media caused by group A beta-hemolytic streptococci, S. pneumoniae (formerly D. pneumoniae), H. influenzae, and staphylococci.
Skin and skin structure infections caused by staphylococci (penicillin-susceptible and penicillin-resistant) and beta-hemolytic streptococci.
Urinary tract infections, including prostatitis, caused by E. coli, P. mirabilis, Klebsiella species, and enterococci (including Enterococcus faecalis). The high concentrations of cephradine achievable in the urinary tract will be effective against many strains of enterococci for which disc susceptibility studies indicate relative resistance.
Three years of qualification
Audited Supplier
Pharma Sources Insight JANUARY 2024
